- The key vendors in the global CINV drugs market 2015-2019 are GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck and TESARO.
London, 05 August 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the global CINV drugs market 2015-2019. One of the key trends being witnessed in this market is the use of combination therapies. These combination therapies have a better safety and efficacy profile, increasing their preference for treating CINV. For instance, Akynzeo, an oral fixed combination of palonosetron and netupitant, helps in preventing nausea and vomiting during acute and delayed phases after cancer chemotherapy. The global CINV drugs market is expected to post a CAGR of 4.9% during the forecast period of 2014-2019.
“Currently, pharmaceutical companies are extensively investing in the discovery and R&D of CINV drugs. For instance, rolapitant by TESARO is an oral formulation that is in its registration stage,” says Faisal Ghaus, Vice President of Technavio Research.
“Moreover, casopitant by GlaxoSmithKline, Zindol by Aphios, and IV formulation of netupitant/palonosetron fixed-dose combination by Helsinn are in phase III developmental stage.”
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
